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Effects of verapamil on the abnormalities in fatty acid
oxidation of myocardium
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Effects of verapamil on the abnormalities in fatty acid oxidation of
myocardium. The oxidation of long (LCFA) and short chain fatty acids
(SCFA) by myocardial mitochondria is impaired in CRF due to reduced
activity of carnitine palmitoyl transferase (CPT) and of enzymes in the
13-oxidation sequence in mitochondrial matrix. It was proposed that
PTH, through its ability to augment entry of calcium into cells,
enhances calcium uptake by the myocardium leading to calcium accu-
mulation which in turn affects mitochondrial function. A calcium
channel blocker may therefore correct these derangements. The present
study examined the effects of verapamil on LCFA and SCFA oxidation
and on CPT activity of myocardial mitochondria and on 45Ca uptake by,
and calcium content of, myocardium obtained from CRF rats and rats
treated with PTH, with and without administration of verapamil. Both
four days of PTH administration and 21 days of CRF produced
significant (P < 0.01) reduction in the oxidation of LCFA and SCFA by
and of CPT activity of myocardial mitochondria and a significant
increase in 45Ca uptake by, and content of, the myocardium. Simulta-
neous administration of verapamil reversed all these derangements.
Administration of verapamil alone to normal rats for 4 or 21 days did not
cause significant changes in these parameters. The results of our studies
are consistent with the notion that the alterations in myocardial
oxidation of LCFA and SCFA in CRF or after PTH treatment are
related to PTH-induced calcium accumulation in the heart, and could be
reversed by a calcium channel blocker. The data could provide a
rational therapeutic approach for the management of uremic myocardi-
opathy.
Oxidation of long and short chain fatty acids by heart
mitochondria is impaired in chronic renal failure (CRF) second-
ary to reduced activity of carnitine palmitoyl transferase (CPT)
and to a defect in /3-oxidation sequence [1]. Available data
indicate that these derangements in fatty acid oxidation are in
large part due to secondary hyperparathyroidism of CRF [1].
Since fatty acids are an important energy source for the heart
under aerobic conditions [2, 3], a defect in their utilization may
contribute to the biochemical derangements underlying the
genesis of uremic myocardiopathy. Therefore, agents that may
reverse or ameliorate the defects in fatty acid oxidation could
provide important therapeutic approach for the management of
myocardial disease in CRF.
The mechanisms through which excess blood levels of para-
thyroid hormone (PTH) exert deleterious effects on fatty acid
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oxidation by the myocardium are not well delineated. However,
it has been suggested that an increase in calcium uptake and/or
content of the myocardium [1] induced by the ability of PTH to
augment calcium entry into cells [4—6] may be responsible, in
large part, for the abnormalities in fatty acid oxidation in CRF.
If this is indeed the case, calcium channel blockers should
improve or correct those derangements in fatty acid oxidation.
The present study examined the effects of verapamil on 45Ca
uptake and calcium content of the myocardium and on long and
short chain fatty acid oxidation and CPT activity of myocardial
mitochondria in animals treated with PTH and in those with
chronic renal failure.
Methods
Male Sprague-Dawley rats weighing 250 to 350 g were used in
the study. The animals were fed normal rat chow (Wayne
Research Animal Diets, Chicago, Illinois, USA) throughout the
study. The diet had 1.4% calcium, 0.97% phosphorus and 4.4
IU/g of vitamin D. Previous studies in our laboratory showed
that a clear cut effect of PTH on mitochondrial fatty acid
oxidation occurs after four days of treatment with the hormone
[1]. Therefore, the present study utilized the four day protocol
of PTH treatment. The animals were housed in individual
cages.
The rats were given an intraperitoneal injection of 200U/day
of 1-84 PTH (Sigma Chemical Company, St. Louis, Missouri,
USA) for four days. The hormone was dissolved in normal
saline and half of the daily dose was given in the morning and
the other half in the late afternoon hours. The control animals
received sham injections containing the vehicle only. A third
group of animals were treated for four days with 1-84 PTH (200
U/day) and simultaneously received subcutaneous injections of
verapamil (Isoptene, Knoll, Ludwigschafen, FRG) in a dose of
0.1 pgIg body weight twice daily. A fourth group of rats
received verapamil only, for four days. Oxidation of a-keto-
glutarate, long chain fatty acid (L-CFA), short chain fatty acid
(S-CFA), and activity of CTP by mitochondria, and 45Ca uptake
and calcium content of the myocardium were examined on the
morning of day 5.
Studies were also performed after 21 days of CRF. The
animals underwent right partial nephrectomy, and a week later
a left nephrectomy was performed. Some of the animals with
CRF received subcutaneous injections of verapamil (0.1 g/g
body wt twice daily) for the 21 day period of CRF. A third group
of normal rats received only verapamil for 21 days. Studies of
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the oxidation of a-ketoglutarate, L-CFA and S-CFA, and CPT
activity in mitochondria, and 45Ca uptake and calcium content
of the myocardium were done on the morning of day 22.
Afterthe animals were sacrificed by decapitation, the hearts
were removed and washed from blood for the isolation of
mitochondria according to the method of Yang, Gieger and
Bessman [71. About 1 g of myocardium was placed in an
ice-cold homogenization media containing 180 mr'i KCI, 10 mM
EDTA disodium with pH adjusted to 7.4. The tissue was then
cut into small pieces, run through a Harvard tissue press and
treated for 30 minutes with trypsin, and then homogenized with
a Dounce type homogenizer. A trypsin inhibitor was then added
to stop the reaction. The mixture was homogenized again and
then centrifuged for 10 minutes, at 400 g, in a Sorvall RC-5
refrigerated centrifuge (DuPont Co., Instrument Produce Divi-
sion, Newton, Connecticut, USA). The pellet was discarded
and the supernatant was centrifuged at 8000 g for 10 minutes,
for final isolation of the mitochondria. The mitochondrial pellet
was washed several times and suspended in a media containing
180 mii KC1, and 10 m Tris HCI and centrifuged for 10
minutes at 8000 g. The pellet was then suspended in media
containing 180 mM KCI, 10 mrvi Tris HCI and 0.5% (wtlvol)
dialyzed albumin. The pH of the media was 7.4. The protein
concentration of the pellet was determined by a modification of
the method of Lowry et al [81. The isolated mitochondria were
used for the study of the oxidation of a-ketoglutarate, L-CFA
and S-CFA and for the activity of CPT. The consumption with
various substrates, respiratory control ratio and ADP:O ratio
were determined polarographically by means of a Clark oxygen
electrode (Gilson Medical Electronics, Middleton, Wisconsin,
USA) fitted to a plexiglass chamber of 2.0 ml capacity as
described originally by Chance and Williams [91. The details for
the study of a-ketoglutarate oxidation have been previously
reported from our laboratory [10]. The amount of ADP added
each time to the oxygraph chamber was 250 pmol. The com-
plete system for fatty acid oxidation contained between 1.0 and
1.5 mg mitochondrial protein added to 2.0 ml of incubation
media containing (in mM): 230 mannitol, 10 Tris HCI, 0.02
EDTA disodium, 5 potassium phosphate, 70 sucrose and 1
malate. The final pH was 7.2 and the temperature 28°C. In the
studies of the oxidation of S-CFA, the media in the oxygraph
chamber contained about 1.0 to 1.5 mg of mitochondrial protein
suspended in 120 liters and 50 p1 of 40 mrvi octanoic acid (Sigma
Chemical Co., St. Louis, Missouri, USA) giving a final concen-
tration of 1.0 m of octanoic acid. The studies for the evalua-
tion of the L-CFA oxidation utilized fatty acid palmitoyl CoA
(Sigma Chemical Co.). To prepare this fatty acid for use in the
study, 1 mg of palmitoyl CoA was added to I ml of 96% ethanol
and sonicated for 10 to 15 minutes, and then diluted with 9 ml of
distilled water. About 1.0 to 1.5 mg mitochondrial protein
contained in 120 p1 of mitochondrial solution, 50 p1 of 2 m of
LD-carnitine, and 30 p1 of 0.1 mrsi palmitoyl CoA were added to
the incubation chamber giving a final concentration 0.05 m of
LD-carnitine and 0.0025 m of palmitoyl CoA. Oxygen con-
sumption was recorded and results were calculated according to
Chance and Williams [9] and expressed as nanomoles of oxygen
utilized per milligram of protein per minute.
The activity of CPT was measured by the method of Bieber,
Abraham and Helmrath [111. This enzyme activity was deter-
mined by the release of free CoA in the presence of exogenous
L-carnitine, palmitoyl CoA and 5.5'-dithiobis-(2 nitrobenzoate)
(DTNB). The free CoA reduced DTNB giving a yellow color
which had a molar absorbance per centimeter of 13.6 X i0 at
412 nm, pH 8.0 and 25°C. To eliminate the effect of endogenous
mitochondrial L-carnitine, a parallel assay was run with excess
D-carnitine which inhibited the reaction (blank); the activity of
the enzyme was then calculated as the difference between
results observed in the presence of L- and D-carnitine and
expressed as nanomoles of CoA per milligram protein per
minute.
The uptake of 45Ca by the myocardium was determined by a
modification of the method of Fleckenstein et al [12]. On the
day of the study, the animals received 20 pCi of 45Ca per kg
body weight, intraperitoneally at 6 a.m. Six hours later the
animals were sacrificed by decapitation, blood was collected
and myocardial samples were obtained, and the wet weight was
determined. The myocardial tissue was dissolved in soluene
X-l00 (Packard Instrument Corp., Downers Grove, Illinois,
USA); 1 ml of soluene was used per 1 mg wet weight. 45Ca in
blood and myocardium was determined with a Beckman liquid
scintillation counter model L 5700 (Beckman Instruments,
Irvine, California, USA). The myocardial uptake of 45Ca was
expressed as percentage uptake in I g wet tissue relative to the
counts in 100 ml of blood.
Myocardial calcium content was also determined. After sac-
rifice by decapitation, myocardial samples were obtained,
washed with saline, and the wet weight was determined. The
samples were then dried in an oven for 24 hours at 105°C. Dry
weight was determined. The tissue samples were then ashed at
400°C for four to six hours. The ash was dissolved in 3 N nitric
acid and calcium concentration was measured with atomic
absorption spectrophotometer (Model 505, Perkin Elmer Cor-
poration, Norwalk, Connecticut, USA).
In all studies, blood samples were obtained for the measure-
ments of calcium with atomic absorption spectrophotometer,
and for inorganic phosphorus and creatinine with an autoana-
lyzer (Technicon Corp., Tarrytown, New York, USA). Data
are expressed as mean SE and statistical significance was
evaluated by parametric t-test.
Results
Table 1 presents the biochemical and mitochondrial data in
the various groups of animals. The plasma levels of creatinine,
calcium and phosphorus were not different among the normal
rats and those treated with PTH alone, PTH and verapamil, and
verapamil alone, except for plasma phosphorus in the PTH
treated rats. In these animals plasma phosphorus (6.5 0.35
mg/dl) was significantly lower than normal. The plasma creati-
nine was significantly (P < 0.01) higher in the rats with CRF
produced by 5/6 nephrectomy than in normal rats. There were
no significant differences between the plasma levels of calcium
and phosphorus in normal rats and in those with CRF with and
without treatment with verapamil.
The respiratory control ratios of the myocardial mitochondria
in the various groups of rats and for the three substrates studied
were within the range of intact mitochondria.
The administration of 1-84 PTH for four days was associated
with marked and significant (P < 0.01) reduction in mitochon-
drial oxidation of a-ketoglutarate, the S-CFA octanoic acid and
the L-CFA palmitoyl CoA (Fig, 1 and Table 1). Treatment with
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Table 1. Effects of 1-84 PTH treatment and chronic renal failure with and without verapamil and of verapamil alone
Normal
4 Days 21 Days
PTH PTH-VER VER CRF CRF-VER VER
Weight g 310 8.6 294 3.3 315 3.4 301 12.9 301 9.3 302 8.6 307 13.9
Serum creatinine mg/dl 0.44 0.03 0.46 0.03 0.48 0.04 0.50 0.04 1.67 0.17 1.45 0.25 0.46 0.03
Serum calcium mg/dl 10.6 0.3 10.6 0.3 10.7 0.2 10.0 0.4 10.2 0.3 10.0 0.3 9.9 0.4
Serum phosphorus mg/d! 8.7 0.10 6.5 0.35 7.9 0.22 8.2 0.36 8.3 0.36 8.0 0.50 8.3 0.35
a-Ketoglutarate
RC ratio 16.2 2.00 12.0 0.60 13.5 0.80 15.4 0.74 15.4 0.57 11.1 0.76 14.9 0.71
ADP:O 2.8 0.05 2.9 0.02 2.6 0.06 2.9 0.08 2.9 0.04 2.8 0.09 2.8 0.04
Oxygen consumption 196 2.4 148 4.Oa 195 2.7 197 2.7 158 19b 193 5.2 202 2.2
nmol/mg protein/mm
Octanoic acid
RC ratio 13.6 1.40 10.1 0.45 8.3 1.10 8.8 0.32 11.7 1.08 9.4 0.93 11.6 1.11
ADP:O 2.5 0.04 2.6 0.04 2.4 0.03 2.5 0.05 2.5 0.03 2.4 0.06 2.6 0.04
Oxygen consumption 169 2.4 132 1.7 173 2.9 168 4.3 149 49b 174 5.6 166 1.6
nmol/mg protein/mm
Palmitoyl CoA
RC ratio 5.5 0.64 4.6 0.44 5.7 0.62 6.4 0.19 4.9 0.41 5.2 0.14 5.6 0.47
ADP:O 2.7 0.06 2.8 0.09 2.8 0.09 2.9 0.13 2.8 0.05 2.7 0.06 2.8 0.05
Oxygen consumption 64 1.1 54 1.8 68 1.8 66 1.3 49 1.6" 65 1.6 67 1.0
nmol/mg protein/mm
Carnitine palmitoyl transferase 17.3 0.64 12.7 0.47a 19.6 1.28 17.5 0.67 13.5 0b 17.6 0.84 17.5 0.62
nmo!Img protein/mm
45Ca uptake %
Calcium content
40 1.9
17 1.2
54 I.?
24 1.8
41 1.7
16 1.8
42 1.9
17 1.4
56 1.8"
25 1.3"
42 1.3
16 1.7
43 2.2
18 1.6
j.g/g dry weight
Abbreviations are: RC, respiratory control; VER, verapamil. The number of animals in normal is 10, in PTH is 13, in PTH-VER is 13, in VER
4 days is 14, in CRF is 10, in CRF-VER is 10, and in VER 21 days is 10. The studies of 45Ca and calcium content were done in 10 rats in each group.
The N in studies with octanoic acid in PTH, PTH-VER and VER 4 days groups is 6.
P < 0.01 compared to normal, to PTH-VER or VER 4 days
b P < 0.01 compared to normal, CRF-VER and VER 21 days.
Fig. 1. Effects of administration of 1-84 PTH with and witfluai treat-
ment with verapamil and of verapamil (VER) alone on oxidation of
a-ketoglutarate (a-KG), long chain fatty acid (L-CFA) and short chain
fatty acid (S-CFA) by myocardia! mitochondria. Each column repre-
sents the mean value and brackets denote I SE. Symbols are: (Li)
normal; (U) 4 days PTH; (D) 4 days PTH + verapamil; (0) 4 days
verapamil.
verapamil reversed these abnormalities. The mitochondrial
oxidation of the three substrates in rats treated with PTH and
verapamil were significantly (P < 0.01) higher than those
observed in rats treated with PTH alone and were not different
from those seen in normal rats (Fig. 1, Table I). Treatment of
normal rats with verapamil alone did not produce significant
changes in mitochondrial oxidation of a-ketoglutarate, octanoic
acid and palmitoyl CoA.
Twenty-one days of CRF was also associated with significant
Fig. 2. Oxygen consumption by myocardial mitochondria from normal
rats (LI), animals with chronic renal failure (•), CRF rats treated with
verapami! () and normal animals given only verapamil (0). Each
column represents mean value and brackets denote I SE.
(P < 0.01) and marked decrements in mitochondrial oxidation
of a-ketoglutarate, octanoic acid and palmitoyl CoA. These
abnormalities were corrected by the treatment with verapamil.
Further, treatment of normal rats for 21 days with verapamil
had no significant effect on mitochondrial oxidation of these
substrates (Fig. 2, Table I).
Both treatment of normal rats for four days with 1-84 PTH
and 21 days of CRF was associated with significant reduction in
the activity of CPT (Figs. 3 and 4). The impairment in the
activity of this enzyme was prevented by the administration of
verapamil to the PTH-treated rats or to the CRF animals.
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Fig. 3. Carnitine palmitoyl transferase activity of myocardial mito-
chondria from normal rats (EU, animals treated with 4 days of 1-84 PTH
(I), those treated simultaneously for 4 days with PTH and verapamil(a), and rats which received 4 days of verapamil alone (0). Each
column represents the mean value and the brackets denote 1 SE.
Fig. 4. Carnitine palmitoyl transferase activity of myocardial miro-
chondria from normal rats (Li), animals with 21 days of chronic renal
failure(•), CRF rats treated with verapamil(), and normal rats given
only verapamil (0). Each column represents mean value and brackets
denote 1 sa.
Verapamil given to normal rats for 21 days had no effect on the
activity of CPT.
Treatment for four days with PTH produced a significant (P
<0.01) increment in 45Ca uptake by and in calcium content of
the myocardium. These changes were corrected by the simul-
taneous administration of verapamil (Table 1). This drug given
to normal rats, however, did not cause significant changes in
myocardial uptake of 45Ca or in myocardial calcium content
(Table 1). Similarly CRF was associated with significant (P <
0.01) augmentation in 45Ca uptake by and in calcium content of
the myocardium. These derangements were reversed by the
treatment of the CRF animals with verapamil (Table 1).
Discussion
We have previously shown that excess blood levels of PTH,
whether produced by exogenous administration of the hormone
or by increased endogenous release of PTH as in CRF, are
associated with marked abnormalities in fatty acid oxidation by
myocardial mitochondria [I]. These derangements were attrib-
uted to reduced activity of CPT, a key enzyme for the transfer
of L-CFA to mitochondrial matrix and to impairment in the
f3-oxidation sequence [1].
However, the mechanisms responsible for the PTH-induced
derangement in the enzymatic steps involved in the oxidation of
the L-CFA and S-CFA were not elucidated. It was suggested
that these effects of PTH may be related to its ability to enhance
entry of calcium into cells [4—6]. Such an effect may result in an
enhanced and prolonged calcium uptake by the myocardium,
resulting in increased calcium content with consequent adverse
effects on the function of myocardial mitochondria. Such a
postulate was based on previous observations that PTH given
to normal rats [10] and CRF in rats [13] were associated with
increased myocardial 45Ca uptake and calcium content and with
impaired oxidation of a-ketoglutarate. These effects were re-
versed by treatment with a calcium channel blocker or by
parathyroidectomy in CRF rats.
The results of the present study are consistent with this
sequence of events. PTH administration to normal rats or CRF
with its attendent secondary hyperparathyroidism were associ-
ated with increased myocardial calcium uptake and content,
reduced activity of CPT and impaired mitochondrial oxidation
of L-CFA and S-CFA. The treatment with verapamil, a calcium
channel blocker, prevented the rise in myocardial calcium
uptake and content, and reversed the derangement in fatty acid
oxidation in both the normal rats treated with PTH and in the
CRF animals.
Similar observations were also reported in skeletal muscle
treated with PTH or in CRF rats [14, 15]. These maneuvers
were also associated with increased skeletal calcium uptake and
impaired CPT activity and L-CFA oxidation. Prevention of the
augmented calcium uptake by a calcium channel blocker was
associated with normalization of the activity of CPT and L-CFA
oxidation.
The results of the present study and those previously re-
ported [1, 10, 13—16] clearly demonstrate that states associated
with excess PTH independent of the presence or absence of
CRF caused marked derangement in myocardial and skeletal
mitochondrial function manifested by impaired mitochondrial
utilization of various substrates, including fatty acids for energy
production. These derangements in mitochondrial oxidation
appear to be related to calcium elevation of the myocardium
and the skeletal muscle.
The derangements in mitochondrial function observed in our
study may play an important role in the myocardiopathy of
CRF. Renal insufficiency is associated with secondary hyper-
parathyroidism in man [17—19], rats [201 and dogs [21]. Al-
though the blood levels of PTH in our animals were not
measured, it is reasonable to assume that a state of secondary
hyperparathyroidism did develop in the rats with CRF and
intact parathyroid glands. The results of the present study in
rats with CRF and those treated with PTH, and our previous
report demonstrating that parathyroidectomy of CRF rats re-
versed the increased 45Ca uptake and calcium content of
myocardium [13] and prevented the abnormalities in fatty acid
oxidation [1], indicate that excess PTH is the culprit; since we
know of no data suggesting that verapamil may inhibit PTH
secretion and since verapamil corrected the calcium overload of
the myocardium and the abnormalities in fatty acid oxidation,
Ca
rn
itin
e p
al
m
ito
yl 
tra
ns
te
ra
se
 
n
m
o
/ C
oA
lm
y p
ro
te
in
/rn
/n
 
0 
I 
•
 
I 
J-
4 
0 
Ca
rn
itin
e 
pa
lm
ito
yl 
tra
rie
fe
re
se
 
n
rn
o
/ C
O
A/
rn
g 
pr
ot
ei
n/
rn
/n
 
0 
0 
I-i
 
Perna et a!. Verapamil effects on fatty acid oxidation 457
we conclude that the beneficial effect of verapamil must have
been mediated by antagonizing the ionophoric property of PTH.
Several lines of evidence indicate that the myocardium is
indeed a target organ for PTH [1, 10, 13, 22—261and that excess
of PTH in patients with chronic renal failure [25, 26] and in
patients with parathyroid adenoma and normal renal function
[27] display myocardial dysfunction. Thus, therapeutic ap-
proaches are needed to ameliorate these deleterious effects of
PTH. The results of our study provide a potential rational
approach for counter balancing the harmful effects of excess
PTH on myocardial function. Indeed, Eren et al [28] treated six
dialysis patients with 250 mg/day of "slow release verapamil"
for three months and found a significant decrease in left
ventricular wall thickness, suggesting a reduction in left ven-
tricular hypertrophy. These changes occurred without a signif-
icant effect on blood pressure.
Such a potential therapeutic effect of verapamil in the man-
agement of the myocardiopathy of CRF provides another
example of the therapeutic benefits of calcium channel blockers
in the management of disturbances in the cardiovascular sys-
tem, such as hypertension, ischemic heart disease and arrhyth-
mias [29]. These actions have also been attributed to the
blocking of calcium entry in the arterial wall or the myocardium
[30].
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